Cargando…

Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity

Although there is a well‐known disparity in prostate cancer (PC) incidence and mortality between Chinese and Western patients, the underlying genomic differences have been investigated only sparsely. This clinicogenomic study was conducted to reveal the genomic mutations contributing to the PC dispa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yu, Zhang, Tingwei, Wang, Beihe, Pan, Jian, Jin, Shengming, Fang, Bangwei, Gu, Weijie, Qin, Xiaojian, Dai, Bo, Lin, Guowen, Gan, Hualei, Wu, Junlong, Ye, Dingwei, Zhu, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552897/
https://www.ncbi.nlm.nih.gov/pubmed/37584393
http://dx.doi.org/10.1002/1878-0261.13511
_version_ 1785116053698772992
author Wei, Yu
Zhang, Tingwei
Wang, Beihe
Pan, Jian
Jin, Shengming
Fang, Bangwei
Gu, Weijie
Qin, Xiaojian
Dai, Bo
Lin, Guowen
Gan, Hualei
Wu, Junlong
Ye, Dingwei
Zhu, Yao
author_facet Wei, Yu
Zhang, Tingwei
Wang, Beihe
Pan, Jian
Jin, Shengming
Fang, Bangwei
Gu, Weijie
Qin, Xiaojian
Dai, Bo
Lin, Guowen
Gan, Hualei
Wu, Junlong
Ye, Dingwei
Zhu, Yao
author_sort Wei, Yu
collection PubMed
description Although there is a well‐known disparity in prostate cancer (PC) incidence and mortality between Chinese and Western patients, the underlying genomic differences have been investigated only sparsely. This clinicogenomic study was conducted to reveal the genomic mutations contributing to the PC disparity across ethnicities and investigate the mutational profile of Chinese PC patients. A total of 1016 Chinese PC patients were prospectively enrolled and subjected to targeted sequencing, resulting in usable sequencing data for 41 genes from 859 patients. Genomic data retrieved from The Cancer Genome Atlas (TCGA; locoregional PC), Memorial Sloan Kettering Cancer Center [MSKCC; metastatic castration‐sensitive PC (mCSPC)], and Stand Up To Cancer [SU2C; metastatic castration‐resistant PC (mCRPC)] cohorts were used as comparators representing Western men. Genomic mutations were analyzed using an integrated bioinformatic strategy. A comparison of the disease stages revealed that mutations in tumor protein 53 (TP53), androgen receptor (AR), forkhead box A1 (FOXA1), and genes involved in the cell cycle pathway were enriched in mCRPC. Mutations in adenomatous polyposis coli (APC) gene were found to be more prevalent in patients with visceral metastasis. Genomic differences between Western and Chinese men were mainly observed in castration‐sensitive PC, with tumors from Chinese men having more FOXA1 (11.4% vs. 4.2%) but fewer TP53 (4.8% vs. 13%) mutations in locoregional PC and harboring fewer TP53 (11% vs. 29.2%), phosphatase and tensin homolog (PTEN; 2.5% vs. 10.3%), and APC (1.7% vs. 7.4%) mutations in the mCSPC stage than those of Western men. Patients of both ethnicities with mCRPC had similar mutational spectra. Furthermore, FOXA1 class‐2 was less common than FOXA1 class‐1 and showed no enrichment in metastasis, contrary to the findings in the Western cohort. Our study provides a valuable resource for a better understanding of PC in China and reveals the genomic alterations associated with PC disparity across races.
format Online
Article
Text
id pubmed-10552897
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105528972023-10-06 Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity Wei, Yu Zhang, Tingwei Wang, Beihe Pan, Jian Jin, Shengming Fang, Bangwei Gu, Weijie Qin, Xiaojian Dai, Bo Lin, Guowen Gan, Hualei Wu, Junlong Ye, Dingwei Zhu, Yao Mol Oncol Research Articles Although there is a well‐known disparity in prostate cancer (PC) incidence and mortality between Chinese and Western patients, the underlying genomic differences have been investigated only sparsely. This clinicogenomic study was conducted to reveal the genomic mutations contributing to the PC disparity across ethnicities and investigate the mutational profile of Chinese PC patients. A total of 1016 Chinese PC patients were prospectively enrolled and subjected to targeted sequencing, resulting in usable sequencing data for 41 genes from 859 patients. Genomic data retrieved from The Cancer Genome Atlas (TCGA; locoregional PC), Memorial Sloan Kettering Cancer Center [MSKCC; metastatic castration‐sensitive PC (mCSPC)], and Stand Up To Cancer [SU2C; metastatic castration‐resistant PC (mCRPC)] cohorts were used as comparators representing Western men. Genomic mutations were analyzed using an integrated bioinformatic strategy. A comparison of the disease stages revealed that mutations in tumor protein 53 (TP53), androgen receptor (AR), forkhead box A1 (FOXA1), and genes involved in the cell cycle pathway were enriched in mCRPC. Mutations in adenomatous polyposis coli (APC) gene were found to be more prevalent in patients with visceral metastasis. Genomic differences between Western and Chinese men were mainly observed in castration‐sensitive PC, with tumors from Chinese men having more FOXA1 (11.4% vs. 4.2%) but fewer TP53 (4.8% vs. 13%) mutations in locoregional PC and harboring fewer TP53 (11% vs. 29.2%), phosphatase and tensin homolog (PTEN; 2.5% vs. 10.3%), and APC (1.7% vs. 7.4%) mutations in the mCSPC stage than those of Western men. Patients of both ethnicities with mCRPC had similar mutational spectra. Furthermore, FOXA1 class‐2 was less common than FOXA1 class‐1 and showed no enrichment in metastasis, contrary to the findings in the Western cohort. Our study provides a valuable resource for a better understanding of PC in China and reveals the genomic alterations associated with PC disparity across races. John Wiley and Sons Inc. 2023-08-23 /pmc/articles/PMC10552897/ /pubmed/37584393 http://dx.doi.org/10.1002/1878-0261.13511 Text en © 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Wei, Yu
Zhang, Tingwei
Wang, Beihe
Pan, Jian
Jin, Shengming
Fang, Bangwei
Gu, Weijie
Qin, Xiaojian
Dai, Bo
Lin, Guowen
Gan, Hualei
Wu, Junlong
Ye, Dingwei
Zhu, Yao
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity
title Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity
title_full Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity
title_fullStr Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity
title_full_unstemmed Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity
title_short Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity
title_sort prospective clinical sequencing of 1016 chinese prostate cancer patients: uncovering genomic characterization and race disparity
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552897/
https://www.ncbi.nlm.nih.gov/pubmed/37584393
http://dx.doi.org/10.1002/1878-0261.13511
work_keys_str_mv AT weiyu prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT zhangtingwei prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT wangbeihe prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT panjian prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT jinshengming prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT fangbangwei prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT guweijie prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT qinxiaojian prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT daibo prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT linguowen prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT ganhualei prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT wujunlong prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT yedingwei prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity
AT zhuyao prospectiveclinicalsequencingof1016chineseprostatecancerpatientsuncoveringgenomiccharacterizationandracedisparity